Lantern Pharma (NASDAQ: LTRN), a clinical-stage precision oncology company using artificial intelligence to develop cancer therapies, announced it will hold a webcast on Aug. 14, 2026, at 9 a.m. ET to discuss its second-quarter financial results and operational highlights. The event, led by President and CEO Panna Sharma and other management members, will cover the quarter ended June 30, 2026, and provide updates on upcoming milestones, clinical trials, and developments involving the company’s RADR® and Open-Medicine AI platforms. A replay will be available on the company’s investor relations website after the event.
The announcement comes as Lantern Pharma continues to advance its pipeline of targeted cancer therapies while expanding the commercial applications of its proprietary AI technologies. The company’s lead candidates include LP-184, an acylfulvene derivative being developed for multiple solid tumors, and LP-284, a TC-NER targeting compound for hematologic and solid tumors. Additionally, LP-300, a cisplatin/ethacraplatin analog, is being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. Through its wholly owned subsidiary Starlight Therapeutics, Lantern is also developing LP-184 for pediatric CNS cancers.
A key focus of the upcoming webcast will likely be the progress of withZeta.ai, Lantern’s multi-agentic AI co-scientist platform, which is now commercially available as a subscription-based research tool for the global biomedical and drug development community. This commercial launch represents a new revenue stream for the company, complementing its core drug development efforts. By offering withZeta.ai to external researchers, Lantern aims to leverage its AI capabilities more broadly, potentially accelerating drug discovery across the industry while generating income to support its own clinical programs.
The company’s RADR® platform, which uses machine learning and AI to analyze vast datasets, remains central to its strategy. RADR is designed to identify patient populations most likely to respond to Lantern’s therapies, thereby increasing the efficiency of clinical trials and improving the odds of success. The Open-Medicine AI platform, which likely refers to collaborative initiatives, may also be discussed, as Lantern continues to emphasize transparency and data sharing in oncology research.
Lantern operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. The company’s focus on AI-driven drug development positions it at the intersection of two rapidly evolving fields: oncology and artificial intelligence. As AI continues to transform pharmaceutical research, Lantern’s ability to generate revenue from its AI platform while advancing its clinical pipeline could provide a diversified business model that appeals to investors.
The webcast will be accessible live and via replay through the investor relations section of Lantern Pharma’s website. For more details, please visit https://ibn.fm/l80kv.
